The abstract is read at the publisher; the summary is JClub's.
The 2024 McDonald diagnostic criteria for multiple sclerosis broaden acceptable evidence, but their safe use outside expert centres is uncertain given variable imaging, labs, and interpretation.
- Why it matters: The key stakes are whether wider evidence rules increase operational feasibility and equity without raising misdiagnosis risk, especially where infrastructure and subspecialist expertise differ.
- What they did: This review evaluates the 2024 criteria as an intervention affecting clinical behaviour, focusing on misdiagnosis risk, feasibility, and equity, including optic nerve findings, the central vein sign, and paramagnetic rim lesions.
- The result: It highlights that more diagnostic pathways may add heterogeneity in practice and proposes safeguards and refinements, including more robust definitions for acquiring and interpreting novel biomarkers.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.